Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

27.35 +1.28 (+4.91%)

Streaming Delayed Price Updated: 9:46 AM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Volume	18,626
Open	26.19
Bid (Size)	26.84 (100)
Ask (Size)	27.75 (500)
Prev. Close	26.07
Today's Range	26.19 - 27.49
52wk Range	6.110 - 44.60
Shares Outstanding	41,793,412
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 20, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

February 09, 2026

From Zenas BioPharma

Via GlobeNewswire

Performance

YTD	-20.7%	-20.7%
1 Month	+41.6%	+41.6%
3 Month	-31.4%	-31.4%
6 Month	+60.9%	+60.9%
1 Year	+290.4%	+290.4%

More News

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Zenas BioPharma

Via GlobeNewswire

Why Is ZBIO Stock Falling Pre-Market Today? ↗

January 06, 2026

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

From Zenas BioPharma

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

January 05, 2026

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

December 15, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

November 11, 2025

From Zenas BioPharma

Via GlobeNewswire

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗

October 31, 2025

Via MarketBeat

1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗

October 28, 2025

Via MarketBeat

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 27, 2025

Via Benzinga

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

October 27, 2025

From Zenas BioPharma

Via GlobeNewswire

Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948 ↗

October 16, 2025

Via The Motley Fool

Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug ↗

October 08, 2025

Via Benzinga

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

October 08, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

September 02, 2025

From Zenas BioPharma

Via GlobeNewswire

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

August 26, 2025

From Zenas BioPharma

Via GlobeNewswire

Frequently Asked Questions

Is Zenas BioPharma, Inc. - Common Stock publicly traded?

Yes, Zenas BioPharma, Inc. - Common Stock is publicly traded.

What exchange does Zenas BioPharma, Inc. - Common Stock trade on?

Zenas BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Zenas BioPharma, Inc. - Common Stock?

The ticker symbol for Zenas BioPharma, Inc. - Common Stock is ZBIO on the Nasdaq Stock Market

What is the current price of Zenas BioPharma, Inc. - Common Stock?

The current price of Zenas BioPharma, Inc. - Common Stock is 27.35

When was Zenas BioPharma, Inc. - Common Stock last traded?

The last trade of Zenas BioPharma, Inc. - Common Stock was at 02/25/26 09:46 AM ET

What is the market capitalization of Zenas BioPharma, Inc. - Common Stock?

The market capitalization of Zenas BioPharma, Inc. - Common Stock is 1.14B

How many shares of Zenas BioPharma, Inc. - Common Stock are outstanding?

Zenas BioPharma, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.